Literature DB >> 31640962

[Prolonged continuous infusion of teriparatide promotes bone metabolism in normal but not in castrated mice].

Minghan Li1, Youhua He1, Guojun Tong1, Dehong Yang1.   

Abstract

OBJECTIVE: To investigate the effects of continuous pumping of teriparatide (TPTD) on bone metabolism in ovariectomized and normal mice and provide experimental evidence for the selection of animal models for studying the effects of TPTD and its related peptides on osteoclasts.
METHODS: Twenty-four female C57BL mice (6-weeks old) were subjected to ovariectomy (OVX) or sham operation followed 7 days later by continuous pumping of TPTD or the solvent vehicle (VEH) via a micropump (SHAM-VEH, SHAM-TPTD, OVX-VEH, and OVX-TPTD groups; n=6). Two weeks later, the tibial and femoral bones were harvested for micro-CT scanning to measure the parameters of the tibia and the femoral cortical bone. Histopathological examinations of the tibial tissue were conducted using HE staining and TRAP staining and the number of osteoclasts and the growth plate thickness were determined. The serum Ca2 + levels of the mice were measured. The primary osteoblasts from the cranial bone were treated with estradiol (E2) and TPTD for 48 h, and the expressions of β-catenin and RANKL protein in the cells were analyzed.
RESULTS: The trabecular bone mass of OVX mice was significantly lower than that of sham-operated mice (P < 0.05). Continuous TPTD pumping significantly reduced tibial cancellous bone mass and femoral cortical bone area in the sham-operated mice, while in the castrated mice, TPTD pumping increased the cancellous bone mass without changing the cortical bone area. TRAP staining showed that cancellous osteoblasts in the tibia increased significantly in the castrated mice as compared with the sham-operated mice, and TPTD pumping significantly increased the number of cancellous osteoblasts in the sham-operated mice (P < 0.05). In the primary cultured osteoblasts, treatment with both E2 and TPTD obviously lowered the expression of β-catenin and increased the expression of RANKL as compared with TPTD treatment alone.
CONCLUSIONS: Continuous pumping of TPTD promotes bone resorption in normal mice but does not produce obvious bone resorption effect in the ovariectomized mice, suggesting that castrated mice are not suitable models for studying the effect of TPTD and the related peptides on the osteoclasts.

Entities:  

Keywords:  continuous stimulation; osteoporosis; parathyroid hormone

Mesh:

Substances:

Year:  2019        PMID: 31640962      PMCID: PMC6881736          DOI: 10.12122/j.issn.1673-4254.2019.09.07

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  28 in total

1.  Modeling of bone formation and resorption mediated by parathyroid hormone: response to estrogen/PTH therapy.

Authors:  Chontita Rattanakul; Yongwimon Lenbury; Nateetip Krishnamara; David J Wollkind
Journal:  Biosystems       Date:  2003-06       Impact factor: 1.973

2.  Anabolic effects of PTH and the 'anabolic window'.

Authors:  Michael Pazianas
Journal:  Trends Endocrinol Metab       Date:  2015-02-05       Impact factor: 12.015

3.  Estrogen inhibition of PTH-stimulated osteoclast formation and attachment in vitro: involvement of both PKA and PKC.

Authors:  Bu-Yuan Liu; Pei-Wen Wu; F Richard Bringhurst; Jeng-Tzung Wang
Journal:  Endocrinology       Date:  2002-02       Impact factor: 4.736

Review 4.  Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives.

Authors:  Roland Baron; Eric Hesse
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

5.  Alendronate improves bone density and type I collagen accumulation but increases the amount of pentosidine in the healing dental alveolus of ovariectomized rabbits.

Authors:  Nilo Guliberto Martins Chavarry; Daniel Perrone; Maria Lucia Fleiuss Farias; Bernardo Camargo Dos Santos; Andrea Castro Domingos; Alberto Schanaider; Eduardo Jorge Feres-Filho
Journal:  Bone       Date:  2018-09-30       Impact factor: 4.398

6.  Effect of raloxifene and its interaction with human PTH on bone formation.

Authors:  Y Lin; L J F Liu; T Murray; J Sodek; L Rao
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

7.  Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation.

Authors:  Glenda J Pettway; Jeffrey A Meganck; Amy J Koh; Evan T Keller; Steven A Goldstein; Laurie K McCauley
Journal:  Bone       Date:  2007-12-15       Impact factor: 4.398

Review 8.  PTH receptor-1 signalling-mechanistic insights and therapeutic prospects.

Authors:  Ross W Cheloha; Samuel H Gellman; Jean-Pierre Vilardaga; Thomas J Gardella
Journal:  Nat Rev Endocrinol       Date:  2015-08-25       Impact factor: 43.330

9.  In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis.

Authors:  W Most; L Schot; A Ederveen; L van der Wee-Pals; S Papapoulos; C Löwik
Journal:  J Bone Miner Res       Date:  1995-10       Impact factor: 6.741

10.  Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide.

Authors:  Akito Makino; Hideko Takagi; Yoshimasa Takahashi; Naoki Hase; Hiroyuki Sugiyama; Kei Yamana; Tsunefumi Kobayashi
Journal:  Calcif Tissue Int       Date:  2018-05-03       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.